Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Eli Lilly’s weight-loss drug tirzepatide significantly reduced sleep apnoea problems in a late-stage ...

Lilly’s investment in new manufacturing capacity comes as demand has surged for its obesity medicine Zepbound, which is sold as ...

Geraniums have long been a stalwart of the British garden Credit: DEB PERRY There are many reasons why geraniums have long been a stalwart of the British garden. Perennially popular due to their ...

Like its rivals in the GLP-1 space, Eli Lilly (NYSE: LLY) continues to explore the potential of Zepbound (tirzepatide ...

The painting of pot red geraniums with whitish centers in a blue and white pot, placed on a white plate with a blue and black ...

The ongoing shortage of Eli Lilly’s popular diabetes med Mounjaro doesn’t look to be letting up anytime soon, with the FDA extending its projection once again. Plus, most doses of the drug’s ...

The 1.5 mg and 4.5 mg doses of Trulicity, another diabetes drug by Lilly, will also be available in limited amounts through April due to increased demand, according to the FDA's website.

Scott Olson / Staff / Getty Images Eli Lilly is set to report earnings Tuesday as investors and analysts expect weight-loss drug demand to continue boosting the company's revenue and profits.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...